Mineralys Therapeutics Inc MLYS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
-
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
-
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
-
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
-
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
-
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $21.64
- Day Range
- $20.12–21.60
- 52-Week Range
- $20.12–47.65
- Bid/Ask
- $20.29 / $24.50
- Shares Outstanding
- 88.41M
- Market Cap
- $1.79B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 76
- Website
- https://mineralystx.com
Valuation
|
Metric
|
MLYS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.26 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MLYS
|
|---|---|
Quick Ratio | 34.24 |
Current Ratio | 34.46 |
Interest Coverage | — |
Quick Ratio
MLYS
Profitability
|
Metric
|
MLYS
|
|---|---|
Return on Assets (Normalized) | −55.61% |
Return on Equity (Normalized) | −59.53% |
Return on Invested Capital (Normalized) | −63.42% |
Return on Assets
MLYS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|br%LKx | LOCK|%^vH | $127B | |||
| Moderna Inc
MRNA
| LOCK|tV<%p^Y | LOCK|$! | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?q>g$>s | LOCK|nFZkF | $81B | |||
| argenx SE ADR
ARGX
| LOCK|S>J@Mm | LOCK|jk! | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|YbFN@K | LOCK|cPz | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%M&hTr | LOCK|c<QFy | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#?#$#z$@ | LOCK|%&?WX | $27B | |||
| Incyte Corp
INCY
| LOCK|FNXsW^ | LOCK|#H | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%#w@WD | LOCK|C# | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|bt??PB | LOCK|Ng | $14B |
United States